OR WAIT null SECS
The new headquarters located in Columbus, Ohio, more than triples Andelyn Biosciences’ footprint to meet growing demand for CGT services.
On June 22, 2023, Andelyn Biosciences, a cell and gene therapy (CGT) contract development and manufacturing organization, announced the opening of its newly constructed manufacturing headquarters in Columbus, Ohio. According to a company press release, the 180,000-ft2 facility is intended to complement Andelyn’s two existing facilities in Columbus.
The new facility houses laboratory and manufacturing space, is regulatory-compliant, and more than triples Andelyn’s footprint to meet the growing demand for CGT services.
“The new facility includes 16 [C]GMP [current good manufacturing practice] modular manufacturing suites with upstream, downstream, solution prep, and filling capabilities, along with quality control labs and warehouse and corporate headquarters space,” said Wade Macedone, CEO, Andelyn Biosciences, in a company press release. “We are proud of our record of success in this demanding field, with over 2000 viral vector production runs and more than 450 [C]GMP batches delivered in support of more than 75 global gene therapy clinical trials.”
Source: Andelyn Biosciences